

Carboplatin

【ICARB】 Carboplatin® 150mg/15mL/Vial

ATC Code : L01XA02

中文名： 剋鉑停靜脈注射液 «杏輝»

適應症： 卵巢癌。

藥理分類： Antineoplastic Agent, Alkylating Agent, Platinum Analog.

用法用量： **Note:**

- Doses for adults are commonly calculated by the target AUC using the Calvert formula, where Total dose (mg) = Target AUC × (GFR + 25).
- If estimating glomerular filtration rate (GFR) instead of a measured GFR, the FDA recommends that clinicians consider capping estimated GFR at a maximum of 125 mL/minute to avoid potential toxicity.
- Carboplatin is associated with a moderate emetic potential in adult patients; antiemetics are recommended to prevent nausea and vomiting.

Administration: IV infusion over 15 minutes or longer.

Indications and dosage regimen:

Ovarian cancer, advanced:

Manufacturer's labeling:

IV: 360 mg/m² every 4 weeks (as a single agent) or 300 mg/m² every 4 weeks (in combination with cyclophosphamide) or Target AUC 4 to 6 (single agent; in previously-treated patients)

Off-label dosing for advanced ovarian cancer:

IV: Target AUC 5 to 7.5 every 3 weeks (in combination with paclitaxel) (Ozols, 2003; Parmar, 2003) or Target AUC 5 every 3 weeks (in combination with docetaxel) (Vasey, 2004)

Bladder cancer (off-label use):

IV: Target AUC 5 every 3 weeks (gemcitabine) or Target AUC 6 every 3 weeks (with paclitaxel).

Breast cancer, metastatic (off-label use):

IV: Target AUC 6 every 3 weeks (with trastuzumab and paclitaxel) or Target AUC 6 every 3 weeks (with trastuzumab and docetaxel).

Cervical cancer, recurrent or metastatic (off-label use):

IV: Target AUC 5 every 3 weeks (with paclitaxel) or Target AUC 5 to 6 every 4 weeks (with paclitaxel) or 400 mg/m² every 28 days (as a single agent).

Endometrial cancer (off-label use):

IV: Target AUC 5 every 3 weeks (with paclitaxel) or Target AUC 2 on days 1, 8, and 15 every 28 days (with paclitaxel).

Esophageal cancer (off-label use):

IV: Target AUC 2 on days 1, 8, 15, 22, and 29 for 1 cycle (with paclitaxel) or Target AUC 5 every 3 weeks (with paclitaxel).

Head and neck cancer (off-label use):

IV: Target AUC 5 every 3 weeks (with cetuximab) or Target AUC 5 every 3 weeks (with cetuximab and fluorouracil) or 300 mg/m² every 4 weeks (with fluorouracil) or Target AUC 6 every 3 weeks (with paclitaxel).

Hodgkin lymphoma, relapsed or refractory (off-label use):

IV: Target AUC 5 (maximum dose: 800 mg) for 2 cycles (with ifosfamide and etoposide).

Malignant pleural mesothelioma (off-label use):

IV: Target AUC 5 every 3 weeks (with pemetrexed).

Melanoma, advanced or metastatic (off-label use):

IV: Target AUC 2 days on 1, 8, and 15 every 4 weeks (with paclitaxel).

Non-Hodgkin lymphomas, relapsed or refractory (off-label use):

IV: Target AUC 5 (maximum dose: 800 mg) per cycle for 3 cycles (with rituximab, ifosfamide and etoposide).

Non-small cell lung cancer (off-label use):

IV: Target AUC 6 every 3 to 4 weeks (with paclitaxel) or Target AUC 6 every 3 weeks (with bevacizumab and paclitaxel) or Target AUC 5 every 3 weeks (with pemetrexed) or with radiation therapy and paclitaxel:

Target AUC 6 every 3 weeks for 2 cycles or

Target AUC 6 every 3 weeks for 2 cycles; then target AUC 2 weekly for 7 weeks or

Target AUC 2 every week for 7 weeks; then target AUC 6 every 3 weeks for 2 cycles

Sarcomas: Ewing sarcoma, osteosarcoma (off-label uses):

IV: 400 mg/m²/day for 2 days every 21 days (in combination with ifosfamide and etoposide) (van Winkle, 2005)

Small cell lung cancer (off-label use):

IV: Target AUC 6 every 3 weeks (with etoposide) or Target AUC 5 every 3 weeks (with irinotecan) or Target AUC 5 every 28 days (with irinotecan).

Testicular cancer (off-label use):

IV: Target AUC 7 as a one-time dose or 700 mg/m²/day for 3 days beginning 5 days prior to peripheral stem cell infusion (with etoposide) for 2 cycles.

Thymic malignancies (off-label use):

IV: Target AUC 5 every 3 weeks (in combination with paclitaxel) (Lemma, 2008)

Unknown primary adenocarcinoma (off-label use):

IV: Target AUC 6 every 3 weeks (with paclitaxel) or Target AUC 6 every 3 weeks (with docetaxel) or Target AUC 6 every 3 weeks (with paclitaxel and etoposide) or Target AUC 5 every 3 weeks (with paclitaxel and gemcitabine)

不良反應：骨髓抑制、噁心、嘔吐、胃腸障礙、聽力障礙、過敏症狀。

注意事項：1.可用 D5W 及 NS 稀釋；不可使用含鋁針頭。
2.稀釋後可在室溫下持續 8 小時的穩定性。
3.外滲之物理性處置方式-冷敷。

懷 孕 期：孕婦使用 carboplatin 注射液會導致胎兒傷害。目前尚無以孕婦為對象的適當且良好的對照研究。患者若要在懷孕期間使用 Carboplatin，或在使用 Carboplatin 期間懷孕，則應告知對胎兒的潛在危險性。應勸告可能懷孕的婦女避孕。

授 乳 期：目前還不清楚此藥是否會分泌至人類乳汁中。因為母親接受 carboplatin 治療可能會對吃母乳的嬰兒產生毒性，建議在接受 carboplatin 治療期間應停止授乳。

使用規定：全民健保--限：1.卵巢癌患者。2.腎功能不佳(CCr < 60)或曾作單側或以上腎切除之惡性腫瘤患者使用。